Navigation Links
Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
Date:10/30/2007

is in 19 multidisciplinary groups. http://www.eortc.be

About Schering-Plough

Schering-Plough Corporation is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 33,500 people around the world. The company's Web site is http://www.scheringplough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to potential market for TEMODAR. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward- looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in Schering-Plough's third quarter 2007 10-Q.

Reference:

(1)National Brain Tumor Foundation Fact Sheet, "Who Gets Brain Tumors and Why"; 2004


'/>"/>
SOURCE Schering-Plough Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
4. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
5. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
6. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
7. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
8. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. UCB Presents Long-Term CImzia Data in Crohns Disease
11. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... and TORONTO , ... ( www.generex.com ) (OTCQB: GNBT) today announced ... a buccal cannabis co-development arrangement with CannScience ... formalized. Generex and CannScience have ... Licensing Agreement.  Pursuant to the Agreement, Generex ...
(Date:9/2/2015)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... for cancer, today announced results for its fiscal year ... http://photos.prnewswire.com/prnh/20140805/133834 "Despite a challenging end ... how the Company is positioned entering fiscal year 2016," ... Chief Executive Officer of MEI Pharma. "While we were ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 Relmada ... novel therapies for the treatment of chronic pain, announced ... meetings at both the FBR Second Annual Healthcare Conference ... as follows: FBR Second Annual Healthcare Conference ... Boston No presentation, investor ...
Breaking Medicine Technology:Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:Americans Living Longer, Healthier Lives Due to Medical Innovation and New Therapies 2Americans Living Longer, Healthier Lives Due to Medical Innovation and New Therapies 3Americans Living Longer, Healthier Lives Due to Medical Innovation and New Therapies 4Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 2Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 3Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 4Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 5Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 6Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 7Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 8Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 9Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 10Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 11Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 12Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 13Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 14Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 15Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 16Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 17Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 18Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 19Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 20Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 21Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 22Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 23Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 24Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 25Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010 26
(Date:9/2/2015)... ... ... to an article published August 12 by International Business Times, a new bill ... grand juries in cases meant to decide if a police officer used deadly or excessive ... in Ferguson and New York City that absolved police officers of charges in the deaths ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and ... gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. ...
(Date:9/2/2015)... Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... featured by the Huffington Post on August 25th, writer Akela Stanfield detailed her ... surgery. While the author acknowledged that she had always seen herself as someone who ...
(Date:9/2/2015)... Covington, LA (PRWEB) , ... September 02, 2015 ... ... new President/CEO and Regulatory Affairs Officer following the departure of Kristen Dietz, former ... Medical Officer of Healtec® released the following statement welcoming Mr. Salot: “ Stanley ...
(Date:9/2/2015)... ... 02, 2015 , ... Density measurement is used in many ... handling makes density measurements more efficient and error-free. The new METTLER TOLEDO video ... and the advantages compared to manual sample handling. , The Evolution of Density ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Healtec® Announces Executive Leadership Change 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3
... , Front-line Caregivers, Nursing Home Residents and Their Family ... Delegation to Stop Potential Cuts , , ... , , RIO RANCHO, N.M., Aug. 11 A ... nursing home residents and their family members to sign a petition that will ...
... , , WELLESLEY HILLS, Mass., ... the PRX-07034 Therapeutics - CNS Phase 2 will be part of the ... , , The PRX-07034 Therapeutics - CNS Phase 2 ... schizophrenia (CIAS). The Company has completed Phase 1 in obesity with ...
... exercise capacity in some mountaineers, according to Swiss researchers. ... been used for years to treat altitude-related symptoms in ... to improve exercise capacity at high altitude. "We ... for preventing high altitude pulmonary edema (HAPE) and dex ...
... It doesn,t affect quality of life in most cases, review ... spares the limbs of some cancer patients may have little ... cost or quality of life, researchers say. , Limb-sparing ... bone or soft-tissue sarcomas, but the analysis by Canadian researchers ...
... Pain therapy for cancer patients whether inpatient or ... the use of an innovative electronic system combined ... been successfully tested. The treatment of the patients showed ... addition, patients reported having less pain. The results of ...
... delivery for older adults developed by researchers from Indiana ... of life, decreased emergency department visits and lowered hospital ... saved money for the sickest (those with three to ... year after the home-based intervention ended, it saved even ...
Cached Medicine News:Health News:New Mexico Seniors to Lose $130.2 Million in Medicare Long Term Care Funding in House Healthcare Reform Bill 2Health News:Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction 2Health News:Taking dex can improve high altitude exercise capacity in certain climbers 2Health News:Taking dex can improve high altitude exercise capacity in certain climbers 3Health News:Limb-Sparing Surgery May Offer Little Benefit to Cancer Patients 2Health News:Computer system improves pain therapy for cancer patients 2Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 2Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 3